# A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy

> **NCT00236717** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 865 (actual)

## Conditions studied

- Epilepsy
- Seizures

## Interventions

- **DRUG:** Topiramate; Carbamazepine; Valproate

## Key facts

- **NCT ID:** NCT00236717
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-09
- **Primary completion:** —
- **Final completion:** 2000-11
- **Target enrollment:** 865 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236717, "A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00236717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*